1. Scrip
  2. >>Business

Cipla’s Proventil Generic Gnaws At US Market

 
• By Anju Ghangurde

Cipla’s generic of Merck & Co’s Proventil makes significant inroads in the US, with the Indian company confident that it has both a strong cost position and large capacity to take on competition. Pricing in the segment currently remains ‘respectable’.

SC1910_Tree-lungs_246277042_1200.jpg
Cipla's albuterol generic makes inroads in the US • Source: Shutterstock

Cipla Limited’s albuterol generic appears to be off to a promising start in the US chipping away at market share, with the company confident of its cost competitiveness and the scope for interchangeability in the segment.

Cipla had in April received the go-ahead for the first generic of Merck & Co., Inc..’s Proventil HFA (albuterol sulfate) metered dose inhaler in the US and the Indian firm said that it has managed to garner 65% share of the Proventil market just four weeks following the launch of its product

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.